{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T21:35:05Z","timestamp":1791668105485,"version":"4.3.4"},"reference-count":41,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2018,1,30]],"date-time":"2018-01-30T00:00:00Z","timestamp":1517270400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Corbus Pharmaceuticals","award":["534126"],"award-info":[{"award-number":["534126"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:p>\n                    Anabasum is a synthetic analog of \u0394\n                    <jats:sup>8<\/jats:sup>\n                    \u2010tetrahydrocannabinol (THC)\u201011\u2010oic acid that in preclinical models of experimental inflammation exerts potent anti\u2010inflammatory actions with minimal central nervous system (CNS) cannabimimetic activity. Here we used a novel model of acute inflammation driven by i.d. UV\u2010killed\n                    <jats:italic>E. coli<\/jats:italic>\n                    in healthy humans and found that anabasum (5\u2009mg) exerted a potent anti\u2010inflammatory effect equivalent to that of prednisolone in terms of inhibiting neutrophil infiltration, the hallmark of acute inflammation. These effects arose from the inhibition of the neutrophil chemoattractant LTB\n                    <jats:sub>4<\/jats:sub>\n                    , while the inhibition of antiphagocytic prostanoids (PGE\n                    <jats:sub>2<\/jats:sub>\n                    , TxB\n                    <jats:sub>2<\/jats:sub>\n                    , and PGF\n                    <jats:sub>2<\/jats:sub>\n                    \u03b1) resulted in enhanced clearance of inflammatory stimulus from the injected site. Anabasum at the higher dose of 20\u2009mg possessed the additional properties of triggering the biosynthesis of specialized pro\u2010resolving lipid mediators including LXA\n                    <jats:sub>4<\/jats:sub>\n                    , LXB\n                    <jats:sub>4<\/jats:sub>\n                    , RvD1, and RvD3. Collectively, we demonstrate for the first time a striking anti\u2010inflammatory and pro\u2010resolution effects of a synthetic analog of THC in healthy humans.\n                  <\/jats:p>","DOI":"10.1002\/cpt.980","type":"journal-article","created":{"date-parts":[[2017,12,14]],"date-time":"2017-12-14T02:12:41Z","timestamp":1513217561000},"page":"675-686","source":"Crossref","is-referenced-by-count":65,"title":["Potent Anti\u2010Inflammatory and Pro\u2010Resolving Effects of Anabasum in a Human Model of Self\u2010Resolving Acute Inflammation"],"prefix":"10.1111","volume":"104","author":[{"given":"Madhur P.","family":"Motwani","sequence":"first","affiliation":[{"name":"Centre for Clinical Pharmacology and Therapeutics, Division of Medicine University College London London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances","family":"Bennett","sequence":"additional","affiliation":[{"name":"Centre for Clinical Pharmacology and Therapeutics, Division of Medicine University College London London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul C.","family":"Norris","sequence":"additional","affiliation":[{"name":"Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative, and Pain Medicine, Brigham and Women's Hospital and Harvard Medical School Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander A.","family":"Maini","sequence":"additional","affiliation":[{"name":"Centre for Clinical Pharmacology and Therapeutics, Division of Medicine University College London London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc J.","family":"George","sequence":"additional","affiliation":[{"name":"Centre for Clinical Pharmacology and Therapeutics, Division of Medicine University College London London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Newson","sequence":"additional","affiliation":[{"name":"Centre for Clinical Pharmacology and Therapeutics, Division of Medicine University College London London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Henderson","sequence":"additional","affiliation":[{"name":"Centre for Clinical Pharmacology and Therapeutics, Division of Medicine University College London London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian J.","family":"Hobbs","sequence":"additional","affiliation":[{"name":"William Harvey Research Institute, Heart Centre, Barts &amp; the London School of Medicine Queen Mary University of London London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Tepper","sequence":"additional","affiliation":[{"name":"Corbus Pharmaceuticals Norwood Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"White","sequence":"additional","affiliation":[{"name":"Corbus Pharmaceuticals Norwood Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles N.","family":"Serhan","sequence":"additional","affiliation":[{"name":"Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative, and Pain Medicine, Brigham and Women's Hospital and Harvard Medical School Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"MacAllister","sequence":"additional","affiliation":[{"name":"Centre for Clinical Pharmacology and Therapeutics, Division of Medicine University College London London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek W.","family":"Gilroy","sequence":"additional","affiliation":[{"name":"Centre for Clinical Pharmacology and Therapeutics, Division of Medicine University College London London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,1,30]]},"reference":[{"key":"e_1_2_8_1_1","doi-asserted-by":"publisher","DOI":"10.1007\/s000110050284"},{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.52.612.631"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxu102"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2016.39"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.06-7227rev"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.7.4345"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.185.2.207"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(76)93021-X"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni1392"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni1182"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.iy.10.040192.001411"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/0167-5699(93)90215-7"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/cjp2.43"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2014.04.062"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm00095a007"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199801)41:1<163::AID-ART20>3.0.CO;2-9"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2008.09.004"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/9550"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.08-118323"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1677\/joe.0.1780029"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.167.2.976"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.1.559"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature08541"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2015.129"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2015.4"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2008-0091TR"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20082058"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3516"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI112825"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature11042"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199801)41:1<163::AID-ART20>3.0.CO;2-9"},{"key":"e_1_2_8_32_1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0022-3565(24)35067-0","article-title":"1',1'\u2010Dimethylheptyl\u2010\u0394\u20108\u2010tetrahydrocannabinol\u201011\u2010oic acid: a novel, orally effective cannabinoid with analgesic and anti\u2010inflammatory properties","volume":"291","author":"Dajani E.Z.","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-016-0373-0"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200314"},{"key":"e_1_2_8_35_1","unstructured":"Spiera R.F.et al.A phase 2 study of safety and efficacy of anabasum (JBT\u2010101) a cannabinoid receptor type 2 agonist in diffuse cutaneous systemic sclerosis. In: ACR Meeting Abstracts [Internet]. <http:\/\/acrabstracts.org\/abstract\/a-phase-2-study-of-safety-and-efficacy-of-anabasum-jbt-101-a-cannabinoid-receptor-type-2-agonist-in-diffuse-cutaneous-systemic-sclerosis\/>."},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1569-1993(17)30160-1"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.85922"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2012.11.010"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.plefa.2016.01.001"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2014-202622"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.plefa.2017.01.004"}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpt.980","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.980","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T15:36:24Z","timestamp":1751124984000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,30]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["10.1002\/cpt.980"],"URL":"https:\/\/doi.org\/10.1002\/cpt.980","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,30]]}}}